This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mehta, J. Articles by Mehta, P. Search for Related Content PubMed PubMed Citation Articles by Mehta, J. Articles by Mehta, P.

Circulation, Vol 60, 497-503, Copyright © 1979 by American Heart Association

ARTICLES

Platelet function studies in heart disease. VI. Enhanced platelet aggregate formation activity in congestive heart failure: inhibition by sodium nitroprusside

J Mehta and P Mehta

We studied 11 patients with congestive heart failure and 10 normal volunteers for in vivo platelet aggregate formation activity. The patients with heart failure had significantly (p less than 0.01) more circulating platelet aggregates than the normal volunteers. During sodium nitroprusside infusion, the number of circulating platelet aggregates declined to normal levels and in vitro platelet aggregation responses to epinephrine and adenosine diphosphate were also suppressed significantly (p less than 0.01). This was associated with a 30% decline in systemic vascular resistance and a 28% increase in cardiac output. In other in vitro experiments, sodium nitroprusside was found to have direct, dose-related platelet aggregation inhibitory actions. This study suggests that an increase in vascular resistance in certain heart failure patients may in part be related to an increase in circulating platelet aggregates. Direct inhibition of platelet aggregation by sodium nitroprusside may be a mechanism of its beneficial effects in heart failure.

This article has been cited by other articles:

				A. Schafer, D. Fraccarollo, J. Widder, M. Eigenthaler, G. Ertl, and J. Bauersachs Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer Eur J Heart Fail, April 1, 2009; 11(4): 336 - 341. [Abstract] [Full Text] [PDF]

				I. Chung and G. Y.H. Lip Platelets and heart failure Eur. Heart J., November 2, 2006; 27(22): 2623 - 2631. [Abstract] [Full Text] [PDF]

				A. Schafer, D. Fraccarollo, M. Eigenthaler, P. Tas, A. Firnschild, S. Frantz, G. Ertl, and J. Bauersachs Rosuvastatin Reduces Platelet Activation in Heart Failure: Role of NO Bioavailability Arterioscler Thromb Vasc Biol, May 1, 2005; 25(5): 1071 - 1077. [Abstract] [Full Text] [PDF]

				V.L. Serebruany, M.E. McKenzie, A.F. Meister, S.Y. Fuzaylov, P.A. Gurbel, D. Atar, W.A. Gattis, and C.M. O'Connor Whole blood impedance aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial) Eur J Heart Fail, August 1, 2002; 4(4): 461 - 467. [Abstract] [Full Text] [PDF]

				C. R. Gibbs, A. D. Blann, R. D. S. Watson, and G. Y. H. Lip Abnormalities of Hemorheological, Endothelial, and Platelet Function in Patients With Chronic Heart Failure in Sinus Rhythm : Effects of Angiotensin-Converting Enzyme Inhibitor and {beta}-Blocker Therapy Circulation, April 3, 2001; 103(13): 1746 - 1751. [Abstract] [Full Text] [PDF]